TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Xbrane Biopharma AB ( (SE:XBRANE) ).
Xbrane Biopharma AB has announced an extra general meeting to discuss a proposed directed issue of shares, which involves issuing up to 1,043,478,260 new shares. This move is aimed at raising capital, with a total potential increase in share capital of SEK 233,933,281.222894. The subscription price is set at SEK 0.23 per share, determined through an accelerated bookbuilding procedure. This strategic decision is expected to strengthen the company’s financial position and support its market expansion efforts, potentially impacting stakeholders by enhancing the company’s capability to compete in the biosimilar market.
More about Xbrane Biopharma AB
Xbrane Biopharma AB operates in the biopharmaceutical industry, focusing on developing and manufacturing biosimilar drugs. The company aims to provide affordable and effective alternatives to existing biologic treatments, targeting a global market for biosimilars.
Average Trading Volume: 20,245,794
Current Market Cap: SEK379.4M
For a thorough assessment of XBRANE stock, go to TipRanks’ Stock Analysis page.